HomeInvestors & MediaNews
- Review paper describing the development status of bispecific antibodies published in Vaccines
- ABL Bio to continue to expand its ‘Grabody’ bispecific antibody platform to bring effective immunotherapy options to patients
July 5, 2021 - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of a peer-reviewed review paper in Vaccines highlighting the potential of bispecific antibodies as the next generation cancer treatment.
Co-authored by Professor Seung-Woo Lee of the Department of Life Sciences at POSTECH and his team, the paper is titled “Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.” In the review, bispecific antibodies are classified into four categories: immune effector cell redirectors, tumor-targeted immunomodulators, dual immunomodulators, and dual tumor-targeting BsAbs. The paper provides an overview of each of these immunotherapies in clinical development as well as strategies to help overcome limitations.
“We are delighted to see our review paper published in Vaccines in collaboration with ABL Bio, a company pioneering research and development efforts in the field of bispecific antibodies,” said Professor Seung-Woo Lee. “We expect this paper to provide key insights into the current status of the development of bispecific antibodies, believed to be the next generation of immunotherapies for cancer patients.”
ABL Bio has developed a set of innovative bispecific antibody platforms and pipelines. Among them, ABL503 (PD-L1 X 4-1BB) and ABL111 (Claudin18.2 X 4-1BB), bispecifics that utilize ‘Grabody-T’ platform technology are currently in Phase 1 clinical trials in the U.S. An investigational new drug (IND) application for ABL501 (LAG-3 X PD-L1) has also been submitted recently to the Ministry of Food and Drug Safety in South Korea. Multiple additional programs are expected to enter clinical trials next year.
“The global market for bispecific antibodies is continuously expanding, reflected in the increasing number of new clinical studies and the recent licensing deals signed by global pharmaceutical companies,” said Sang Hoon Lee, Ph.D., CEO of ABL Bio. “We plan to continue to expand our Grabody platforms to build a more robust bispecific antibody portfolio that can offer safe and promising treatment options.”
About ABL Bio
ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com